J Boustani1,2, A Ruffier3, A Moya-Plana4, Y Tao3, F Nguyen3, C Even4, C Berthold3, O Casiraghi5, S Temam4, P Blanchard3. 1. Department of Radiation Oncology, Georges François Leclerc, Dijon, France. boustanijihane@hotmail.com. 2. Department of Radiation Oncology, Gustave Roussy, 114 rue Edouard Vaillant, 94800, Villejuif, France. boustanijihane@hotmail.com. 3. Department of Radiation Oncology, Gustave Roussy, 114 rue Edouard Vaillant, 94800, Villejuif, France. 4. Department of Head and Neck Oncology, Gustave Roussy, Villejuif, France. 5. Department of Pathology, Gustave Roussy, Villejuif, France.
Abstract
PURPOSE: To determine outcomes and toxicities after reirradiation for locally recurrent nasopharyngeal carcinoma (rNPC) and to apply a prognostic index in a non-endemic region. METHODS: We retrospectively reported progression-free survival (PFS), overall survival (OS), and treatment-related toxicities in patients treated with curative intent for locally rNPC. We applied the prognostic model for OS and grade 5 radiotherapy (RT)-related toxicities published by Li et al. and evaluated its prognostic accuracy by receiver operating characteristic (ROC) curve analysis. RESULTS: Between 2005 and 2018, 33 patients were treated for rNPC in our institution. Median follow-up was 60 months. The mean time to local recurrence was 75 months. Six (18%) patients had a persistent grade 3 toxicity from a previous RT course. The median re-RT dose was 66 Gy. After re-RT, 13 patients had local failure and 3 patients had metastatic recurrence. Median PFS was 18 months with a 5-year PFS rate of 29%. Median OS was 35 months with a 5-year OS rate of 37%. Grade 3 or higher toxicities rate was 74%. There were 21% grade 5 toxicities. The median time to a grade 5 toxicity was less than 6 months following re-RT. The prognostic nomogram was not predictive for OS or grade 5 toxicities. CONCLUSION: Reirradiation of rNPC is an effective treatment but is associated with a high rate of life-threatening toxicity. Stratification of patients based on their risk of developing severe toxicity is needed to select patients who will most likely benefit from re-RT.
PURPOSE: To determine outcomes and toxicities after reirradiation for locally recurrent nasopharyngeal carcinoma (rNPC) and to apply a prognostic index in a non-endemic region. METHODS: We retrospectively reported progression-free survival (PFS), overall survival (OS), and treatment-related toxicities in patients treated with curative intent for locally rNPC. We applied the prognostic model for OS and grade 5 radiotherapy (RT)-related toxicities published by Li et al. and evaluated its prognostic accuracy by receiver operating characteristic (ROC) curve analysis. RESULTS: Between 2005 and 2018, 33 patients were treated for rNPC in our institution. Median follow-up was 60 months. The mean time to local recurrence was 75 months. Six (18%) patients had a persistent grade 3 toxicity from a previous RT course. The median re-RT dose was 66 Gy. After re-RT, 13 patients had local failure and 3 patients had metastatic recurrence. Median PFS was 18 months with a 5-year PFS rate of 29%. Median OS was 35 months with a 5-year OS rate of 37%. Grade 3 or higher toxicities rate was 74%. There were 21% grade 5 toxicities. The median time to a grade 5 toxicity was less than 6 months following re-RT. The prognostic nomogram was not predictive for OS or grade 5 toxicities. CONCLUSION: Reirradiation of rNPC is an effective treatment but is associated with a high rate of life-threatening toxicity. Stratification of patients based on their risk of developing severe toxicity is needed to select patients who will most likely benefit from re-RT.
Entities:
Keywords:
Head and neck cancer; Prognostic nomogram; Radiotherapy; Recurrence
Authors: Dora L W Kwong; Jonathan S T Sham; Lucullus H T Leung; Ashley C K Cheng; W M Ng; Philip W K Kwong; W M Lui; C C Yau; P M Wu; William Wei; Gordon Au Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-05 Impact factor: 7.038
Authors: Gang Peng; Tao Wang; Kun-Yu Yang; Sheng Zhang; Tao Zhang; Qin Li; Jun Han; Gang Wu Journal: Radiother Oncol Date: 2012-09-17 Impact factor: 6.280
Authors: A Dimitrios Colevas; Sue S Yom; David G Pfister; Sharon Spencer; David Adelstein; Douglas Adkins; David M Brizel; Barbara Burtness; Paul M Busse; Jimmy J Caudell; Anthony J Cmelak; David W Eisele; Moon Fenton; Robert L Foote; Jill Gilbert; Maura L Gillison; Robert I Haddad; Wesley L Hicks; Ying J Hitchcock; Antonio Jimeno; Debra Leizman; Ellie Maghami; Loren K Mell; Bharat B Mittal; Harlan A Pinto; John A Ridge; James Rocco; Cristina P Rodriguez; Jatin P Shah; Randal S Weber; Matthew Witek; Frank Worden; Weining Zhen; Jennifer L Burns; Susan D Darlow Journal: J Natl Compr Canc Netw Date: 2018-05 Impact factor: 11.908
Authors: You Quan Li; Yun Ming Tian; Sze Huey Tan; Ming Zhu Liu; Grace Kusumawidjaja; Enya H W Ong; Chong Zhao; Terence W K Tan; Kam Weng Fong; Kiattisa Sommat; Yoke Lim Soong; Joseph T S Wee; Fei Han; Melvin L K Chua Journal: J Clin Oncol Date: 2018-02-07 Impact factor: 44.544
Authors: F Perri; G Della Vittoria Scarpati; F Caponigro; F Ionna; F Longo; S Buonopane; P Muto; M Di Marzo; S Pisconti; R Solla Journal: Onco Targets Ther Date: 2019-02-26 Impact factor: 4.147
Authors: J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray Journal: Int J Cancer Date: 2018-12-06 Impact factor: 7.396